Table 3.
Relationship between clinico-pathologic features, MSI status, and PTENP1 expression.
| PTENP1 expression | ||||
|---|---|---|---|---|
|
|
|
|
|
|
| Total (n) | Positive (%) | Negative (%) | p value | |
|
| ||||
| Number of patients | 61 | 34 (56%) | 27 (44%) | |
|
| ||||
| Stage | 0.97a | |||
|
| ||||
| I and II | 25 | 14 (56%) | 11 (44%) | |
|
| ||||
| III and IV | 36 | 20 (56%) | 16 (44%) | |
|
| ||||
| Grade | 0.73a | |||
|
| ||||
| 1 | 20 | 12 (60%) | 8 (40%) | |
|
| ||||
| 2 | 22 | 11 (50%) | 11 (50%) | |
|
| ||||
| 3 | 18 | 11 (61%) | 7 (39%) | |
|
| ||||
| Recurrence/progression | 0.11a | |||
|
| ||||
| Yes | 27 | 12 (44%) | 15 (56%) | |
|
| ||||
| No | 34 | 22 (65%) | 12 (35%) | |
|
| ||||
| MSI | 0.76a | |||
|
| ||||
| Yes | 28 | 16 (57%) | 12 (43%) | |
|
| ||||
| No | 33 | 18 (55%) | 15 (45%) | |
a
Two-tailed Chi-square test.